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Closure After Sapien 3 Transcatheter
Aortic Valve Replacement
Sharayne D. Mark, MD, Vikram Prasanna, MD, Victor A. Ferrari, MD, Howard C. Herrmann, MDA n 89-year old man with severe, symptomaticaortic stenosis (Society of Thoracic Surgeonsestimated mortality of 5.6%) underwent
transcatheter aortic valve replacement (TAVR) with
a #29 Sapien 3 (Edwards Lifesciences, Inc., Irvine,
California) prosthesis as part of the PARTNER
trial (Placement of Aortic Transcatheter Valve Trial)
intermediate-risk registry cohort. Post-operatively,
a new asymptomatic restrictive membranous
ventricular septal defect (VSD) was noted on trans-
thoracic echocardiogram, a rare complication post–
transcatheter aortic valve replacement (1,2). One
month later, he presented with a progressive nonpro-
ductive cough and dyspnea. A transesophageal echo-
cardiogram revealed a larger VSD and new left
ventricular dysfunction (Figure 1A, Online Video 1;
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Manuscript received November 28, 2014; revised manuscript received Decemdemonstrated a Qp/Qs ratio of 1.6:1. The decision
was made to repair the VSD with a transcatheter
closure device. Under general anesthesia and trans-
esophageal echocardiographic guidance, percuta-
neous VSD closure was performed with an
Amplatzer Muscular VSD occluder (St. Jude Medi-
cal, Inc., St. Paul, Minnesota) (10-mm diameter)
with an anterograde arteriovenous loop technique.
No signiﬁcant shunting was observed post-
deployment (Figures 1B, 1D, 1E, and 1F, Online Videos
2, 3, 5, and 6).
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FIGURE 1 VSD Pre- and Post-Percutaneous Closure
(A) Anterior posterior left ventriculogram revealing contrast media shunted across the ventricular septal defect (VSD) (arrow, Online Video 1). (B) Left
anterior oblique ﬂuoroscopy with the Edwards Sapien 3 valve (arrowhead), and directly posterior to it sits the Amplatzer (arrow, Online Video 2). (C) Apical
4-chamber color transesophageal echocardiogram compared with 2-dimensional view, revealing a moderate-sized VSD (arrow, Online Video 3). (D) Post-
Amplatzer revealing a small residual VSD (arrow, Online Video 4). (E) Post-Amplatzer transesophageal echocardiogram 3-dimensional reconstruction
(arrow, Online Video 5). (F) Post-Amplatzer transthoracic echocardiogram apical 4-chamber color Doppler (arrow, Online Video 6).
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APPENDIX For supplemental videos and
their legends, please see the online version of
this article.
